ArticlePulmonary circulation2024

CS1, a controlled-release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial.

Raymond L Benza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.